Benchmark Reaffirms Buy Rating for Integer (NYSE:ITGR)

Benchmark reiterated their buy rating on shares of Integer (NYSE:ITGR) in a research note published on Friday morning, Benzinga reports. The firm currently has a $130.00 target price on the medical equipment provider’s stock.

Several other brokerages have also recently commented on ITGR. CL King started coverage on shares of Integer in a report on Thursday, March 14th. They set a buy rating and a $137.00 target price on the stock. Bank of America raised Integer from a neutral rating to a buy rating and lifted their price objective for the company from $105.00 to $135.00 in a report on Monday, April 15th. Finally, KeyCorp increased their target price on Integer from $123.00 to $139.00 and gave the stock an overweight rating in a report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $120.50.

Integer Stock Down 1.4 %

ITGR stock opened at $109.58 on Friday. Integer has a 1-year low of $69.40 and a 1-year high of $123.99. The firm has a market capitalization of $3.67 billion, a PE ratio of 37.92, a PEG ratio of 1.52 and a beta of 1.10. The business’s 50 day simple moving average is $113.11 and its 200 day simple moving average is $100.07. The company has a current ratio of 3.32, a quick ratio of 1.71 and a debt-to-equity ratio of 0.76.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. Integer had a return on equity of 11.25% and a net margin of 6.01%. The company had revenue of $414.80 million during the quarter, compared to analysts’ expectations of $412.78 million. During the same quarter in the previous year, the company posted $0.87 earnings per share. The business’s revenue was up 9.5% on a year-over-year basis. As a group, research analysts anticipate that Integer will post 5.27 EPS for the current year.

Institutional Trading of Integer

Several large investors have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Integer by 2,037.3% in the third quarter. SG Americas Securities LLC now owns 26,289 shares of the medical equipment provider’s stock worth $2,062,000 after acquiring an additional 25,059 shares during the last quarter. Raymond James & Associates boosted its position in Integer by 4.0% in the third quarter. Raymond James & Associates now owns 40,700 shares of the medical equipment provider’s stock valued at $3,192,000 after buying an additional 1,564 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Integer by 16.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,902 shares of the medical equipment provider’s stock worth $384,000 after buying an additional 684 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Integer by 2.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,489 shares of the medical equipment provider’s stock worth $1,293,000 after buying an additional 353 shares in the last quarter. Finally, Park Avenue Securities LLC bought a new position in shares of Integer in the 3rd quarter valued at $462,000. 99.29% of the stock is owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.